¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"asymmetric strand transfer model"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • psychodynamic experiential model
    Á¤½Å¿ªµ¿°æÇè¸ðÇü
  • reserve model
    ¿¹ºñ¸ðÇü
  • role model
    ¿ªÇÒÇ¥º»Çü, ¿ªÇÒ¸ðµ¨
  • social service model
    »çȸ¼­ºñ½º¸ðµ¨
  • statistical model
    Åë°è¸ðÇü
  • symmetry model
    ´ëĪÇü, ´ëμ³
  • sequential model
    ¼øÂ÷¸ðµ¨
  • single major gene locus model
    ´ÜÀÏÁÖ¿äÀ¯ÀüÀÚÀÚ¸®¸ðÇü
  • viscoelastic model
    Á¡µµÅº·Â¸ðÇü
  • working model
    ÀÛ¾÷¸ðÇü
  • wax model
    ¹Ð¶ø¸ðÇü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • demonstration model
    ½Ã¹ü¸ðÇü
  • fluid mosaic model
    À¯µ¿¸ðÀÚÀÌÅ©¸ðµ¨
  • general linear model
    ÀϹݼ±»ó¸ðµ¨
  • gnathostatic model
    ÅθðÇü, ¾ÇŸðÇü
  • health belief model
    °Ç°­¹ÏÀ½¸ðÇü
  • homeostatic model
    Ç׻󼺸ðÇü
  • in-the-ear model
    ±Í¼ÓÇüº¸Ã»±â
  • linear quadratic model
    ¼±Çü¹æÇü¸ðµ¨, ¼±ÇüÀÌÂ÷ÇÔ¼ö¸ðµ¨
  • model
    ¸ðÇü, ¸ðµ¨
  • model population
    ¸ðÇüÀα¸
  • model psychosis
    ¸ðÇüÁ¤½Åº´
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multistage model
    ´Ù´Ü°è¸ðÇü
  • multitarget model
    ´ÙÇ¥Àû¸ðµ¨
  • multitarget multihit model
    ´ÙÇ¥Àû´ÙÀûÁ߸ðµ¨
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • stress and coping model
    ½ºÆ®·¹½º¿Í ´ëó(Óßô¥)¸ðµ¨.
  • symmetry model
    ´ëĪÇü(Óßöàúþ), ´ëμ³(Óß öàæò).
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸¼º »ó´ëÀ§Çè¸ðµ¨
  • viscoelastic model
    Á¡Åº¼º¸ðÇü.
  • wave model
    ÆÄÇü
  • wax model
    ³³(¿ø)Çü(ÕÅê«úþ).
  • working model
    ÀÛ¾÷¸ðÇü(ËöËâËÎÌ´).
  • working model for bridgework
    ±³ÀÇÄ¡¿ë ÀÛ¾÷¸ðÇü(ÎéëùöÍéÄíÂåöÙ¼úþ).
  • adoptive transfer
    ÀÎÀÔ(¸é¿ª)Àü´Þ(ìÚìýØóæ¹îîÓ¹).
  • adoptive transfer
    ÀÔ¾çÀü´Þ
  • afterimage transfer test
    ÀÜ»óÀüÀ̰˻ç
  • antibody transfer
    Ç×üÀÌÀÔ(¡­ì¹ìý).
  • conjugal transfer
    Á¢ÇÕÀü´Þ
  • drug resistance transfer factor
    ¾àÁ¦³»¼ºÀü´ÞÀÎÀÚ
  • electron transfer
    ÀüÀÚÀ̵¿(¡­ì¹ÔÑ), ÀüÀÚ¿î¹Ýü(¡­ê¡Úæô÷).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • methyl-poor transfer RNA
    °ú(Íû)¸ÞÆ¿ Àü´Þ(îîÓ¹)RNA
  • modulator transfer RNA
    Á¤Á¶ÀÚ(ïÚðàí­) Àü´Þ(îîÓ¹) RNA
  • noncollisional energy transfer
    ºñÃæµ¹(ÞªõúÔÍ)¿¡³ÊÁöÀü´Þ(îîÓ¹)
  • passive transfer
    ¼öµ¿ À̵¿(áôÔÑì¹ÔÑ)
  • phase transfer
    »óÀüÀÌ(ßÓï®ì¹)
  • phosphate group transfer
    Àλê±â ÀüÀÌ(×òß«Ðñï®ì¹)
  • phosphate transfer potential
    ÀλêÀüÀÌ ÀüÀ§(×òß«ï®ì¹ï³êÈ)
  • phosphoryl-group transfer
    ÀλêÈ­±â ÀüÀÌ(×òß«ûùÐñï®ì¹)
  • phosphoryl transfer potential
    ÀλêÈ­ ÀüÀÌ ÀüÀ§(×òß«ûùï®ì¹ï³êÈ)
  • plasmid transfer
    Çö󽺹̵å Àü´Þ(îîÓ¹)
  • precursor transfer RNA
    Àü´Þ(îîÓ¹) RNA Àü±¸Ã¼(îñÏÌô÷)
  • pre-transfer RNA
    Àü±¸(îñÏÌ)ÀüÀÌ(ï®ì¹)RNA
  • proton transfer potential
    ¾ç¼ºÀÚ(åÕàõí­) ÀüÀÌ ÀüÀ§(ï®ì¹ï³êÈ)
  • resistance-transfer factor
    ÀúÇ×ÀüÀÌ ÀÎÀÚ(ï®ì¹ì×í­)
  • resonance energy transfer
    °ø¸í(ÍìÙ°) ¿¡³ÊÁö ÀüÀÌ(ï®ì¹)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
OSI open systems interconnection [reference model]
PBPK physiologically based pharmacokinetic [model]
PDM point distribution model
PRECEDE predisposing, reinforcing, and enabling causes in educational diagnosis and evaluation [model]
PROC GLM general linear model procedure
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
DSB Double-strand DNA break
PCR-SSCP PCR single-strand conformation polymorphism
SSCP PCR)-Single Strand Conformation Polymorphism
PCR-SSCP Polymerase Chain Reaction-Single Strand Conformation Polymorphism
PCR-SSCP Polymerase chain reaction and single strand conformation polymorphism
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
transition probability model A model to account for the apparently random variation in cell cycle time between individual animal tissue cells in culture that postulates that transition from G1 to s phase is probabilistic. Contrasts with hypotheses that require the accumulation of critical levels of particular proteins.
(18 Nov 1997)
KNF model <abbreviation> Koshland-Nemethy-Filmer model.
(05 Mar 2000)
Koshland-Nemethy-Filmer model <biochemistry, chemistry> A model to explain the allosteric form of cooperativity; in this model, in the absence of ligands, the protein exists in only one conformation; upon binding, the ligand induces a conformational change that may be transmitted to other subunits.
Synonym: Adair-Koshland-Nemethy-Filmer model, induced fit model.
(05 Mar 2000)
fluid bilayer model Generally accepted model for membranes in cells. In its original form, the model held that proteins floated in a sea of phospholipids arranged as a bilayer with a central hydrophobic domain. Although it is now recognised that some proteins are restrained by interactions with cytoskeletal elements and that the phospholipid annulus around a protein may contain only specific types of lipid, the model is still considered broadly correct.
(18 Nov 1997)
fluid mosaic model A model used to conceptualise cell membranes, in it, the membranesare described as a structually and functionally asymmetric lipidbilayer studded with embedded proteins that aid in cross-membrane transport.
(09 Oct 1997)
lock-and-key model A model used to suggest the mode of operation of an enzyme in which the substrate fits into the active site of the protein like a key into a lock.
(05 Mar 2000)
logistic model A statistical model; in epidemiology, a model of risk as a function of exposure to a risk factor.
(05 Mar 2000)
adoptive transfer Form of passive immunization where previously sensitised immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (immunotherapy, adoptive).
(12 Dec 1998)
gamete intra-fallopian transfer <gynaecology> Gamete intra-fallopian transfer is a technique that involves combining eggs and sperm outside of the body and immediately placing them into the fallopian tubes to achieve fertilization.
A technique that came into use in the mid-1980's for assisted conception in infertile women with normal fallopian tubes. The protocol consists of hormonal stimulation of the ovaries, followed by laparoscopic follicular aspiration of oocytes, and then the transfer of sperm and oocytes by catheterization into the fallopian tubes.
Acronym: GIFT
(12 Dec 1998)
gel transfer Any lab technique used to transfer substances which had been separated using gel electrophoresis from the gel to a membrane for further processing or analysis. For example: any type of blotting.
(09 Oct 1997)
gene transfer <molecular biology> General tem for the insertion of foreign genes into a cell or organism. Synonymous with transfection.
(18 Nov 1997)
cavernous transfer of portal vein <anatomy, vein> Replacement of the portal vein by a number of collateral channels, a consequence of thrombosis.
(05 Mar 2000)
patient transfer Interfacility or intrahospital transfer of patients. Intrahospital transfer is usually to obtain a specific kind of care and interfacility transfer is usually for economic reasons as well as type of care provided.
(12 Dec 1998)
resistance-transfer factor The transfer gene of the resistance plasmid.
(05 Mar 2000)
resonance energy transfer <technique> Transfer of energy from one fluorochrome to another. The emission wavelength of the fluorochrome excited by the incident light must approximately match the excitation wavelength of the second fluorochrome.
If light at the second emission wavelength is detected, it implies that the two fluorochromes were physically within a few nanometres. Used as a technique to probe protein or cell interactions.
(25 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á